Archives: PDF

To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion.

To analyze the long-term efficacy of 577 nm sub-threshold micropulse yellow laser (SMYL) in the treatment of chronic central serous chorioretinopathy (CCSC) and to evaluate the anatomic outcome, visual results and safety profile of the treatment.

This case involves a 28-year-old man who has type 1 diabetes and severe nonproliferative diabetic retinopathy. I asked the patient to return for follow-up in 3 months. Two years later, the patient returned with early neovascularization of the disc (NVD) with 20/20 visual acuity (Figure 1). What are you going to do?

Chronic central serous chorioretinopathy is a serious therapeutic problem, as it may lead to significant visual impairment. To date, various invasive and non-invasive treatment methods have been tried with only moderate success.

As the worldwide population ages, diabetic macular edema (DME) and associated retinal conditions represent an increasingly significant burden to the health care system. Cost and treatment burden are two of the critical factors that influence the viability of available treatment options.

Micropulse laser treatment is an alternative to the conventional continuous-wave laser for the treatment of retinal or macular diseases. In contrast to the conventional laser, the therapeutic effect of the subthreshold micropulse laser is not accompanied by thermal retinal damage.

I was part of the Pan American Collaborative Retina Study (PACORES) that compared yellow SubLiminal laser with photodynamic therapy (PDT) in eyes with chronic central serous chorioretinopathy (CSCR) (unpublished data).

I would like to introduce you to the principle of MicroPulse laser therapy. To understand MicroPulse laser technology, we must first understand conventional photocoagulation. With conventional photocoagulation, the laser transfers energy to the retina.

To compare the short-term treatment outcome of the 577 nm subthreshold micropulse laser (SML) and half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (cCSC) and persistent subretinal fluid (SRF).

To compare the efficacy and safety of subthreshold micropulse yellow wavelength laser (SMYL) and low-fluence photodynamic therapy (PDT) in the treatment of chronic central serous chorioretinopathy (CSC).